Approved by the FDA in July to treat adults with early symptomatic Alzheimer’s disease, Eli Lilly’s Kisunla reduced the brain ...

Eli Lilly is set to report Q3 earnings Wednesday, as the pharma giant continues to gain market share in the weight loss drug space.

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Eli Lilly & Co. reported its results for the third quarter of 2024, with revenue up 20% y/y but failing to meet market ...

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55 ...

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that ...

This summary highlights recent health news including the bird flu outbreak in Romania, Alzheimer's drug trials by Coya ...

Eli Lilly and Company. "Donanemab demonstrated meaningful results for people with early symptomatic Alzheimer's disease by ...

Eli Lilly reported third-quarter adjusted profit and revenue that missed expectations, sending its stock tumbling roughly 10% ...

Modified titration was associated with a 41% lower relative risk of ARIA-E than the standard dosing regimen. Topline results were announced from a phase 3b trial evaluating various dosing regimens of ...